By Assoc. Prof. Dr. Mehmet Sorar | Published: 05.02.2025
Parkinson Plus and TMS: What Does the Research Show?
Transcranial magnetic stimulation (TMS), which sends magnetic pulses into the brain through a coil on the scalp, has not been shown to help people with multiple system atrophy (MSA), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) or dementia with Lewy bodies (DLB). The few studies are small, and none measured disease progression or survival. Care for these conditions remains mostly symptom-based.
Is TMS an established treatment for these conditions?
No. Cleveland Clinic lists four uses cleared by the US Food and Drug Administration (FDA): depression, acute treatment of migraine with aura (with a handheld single-pulse device), obsessive compulsive disorder, and short-term help with quitting smoking. The same page names Parkinson's disease as a condition under study but not cleared. MSA, PSP, CBD and DLB are not on its list.
The European guideline by Lefaucheur and colleagues reviewed the literature up to the end of 2018. It found definite efficacy (Level A) for only three uses, and probable efficacy (Level B) for a short list that includes Parkinson's disease, for movement symptoms or depression. Its abstract says no other condition reached Level A or B, and MSA, PSP, CBD and DLB are not among those listed. The Parkinson's disease finding cannot be carried over to the conditions on this page, which are separate diagnoses; see What is Parkinson's disease? for that condition. The authors also remind readers that a benefit supported by statistics does not always matter in daily life.
What has been studied in multiple system atrophy?
Zhang and colleagues reviewed non-invasive brain stimulation, including TMS, in MSA in 2021. They found nine studies with 123 people, published between 2013 and 2020, and the picture is small:
- Five studies were in the parkinsonian type (MSA-P), three in the cerebellar type (MSA-C) and one mixed.
- Four were randomised trials comparing real with sham stimulation (a sham session imitates stimulation without delivering it), with 19, 15, 6 and 50 people. The rest were a 9-person study without a control group, two studies compared with other patient groups, and two single-patient reports.
- The largest trial, in 50 people with MSA-C, gave 10 sessions of intermittent theta-burst TMS over the cerebellum and reported better scores than sham on an ataxia scale (SARA; ataxia means loss of balance and coordination). A 19-person MSA-P trial gave 10 sessions of 5 Hz TMS over the left motor cortex and reported better scores than sham on the motor section of a rating scale (UMSARS).
- The authors rated quality as mixed: scores on a standard quality scale ranged from 4 to 8, three studies were rated high quality and four moderate, none described allocation concealment, and only three blinded both participants and therapists.
The authors say there is not sufficient confidence in the findings because the studies are few and of low quality. They call brain stimulation a possibly useful rehabilitation strategy and ask for high-quality trials with standard protocols and long-term follow-up. The outcomes were movement and ataxia scores and imaging changes after one to ten sessions. Only one study looked at thinking, and side effects are not clearly set out study by study.
What do the studies of PSP, CBD and DLB show?
Very little. PSP has one small single-session trial, CBD has a two-person report, and no published TMS treatment trial was found in DLB.
| Condition | What was found | What was measured | Limit |
|---|---|---|---|
| PSP | Pilotto and colleagues: 20 people in a double-blind, sham-controlled crossover trial. Each person had one real and one sham session of cerebellar theta-burst TMS. | Time standing without falling in two balance positions was longer after real stimulation (p = 0.04 for each) and sway was reduced (p between 0.005 and 0.008). | One session and short-term balance only. Nothing on falls in daily life, lasting benefit or disease course. |
| CBD (corticobasal syndrome) | Civardi and colleagues: a report of two people, the only TMS treatment report found. | A nerve test (the cortical silent period) lengthened briefly after slow TMS. | No symptoms or function were measured, so there is no evidence of clinical benefit. |
| DLB | No published treatment trial found. | Not applicable. | Petsani and colleagues describe research in Lewy body disease as preliminary. |
A planned follow-up study in PSP (10 days of cerebellar TMS in 30 people) had reached only the protocol stage at last check, with no results found. Petsani and colleagues reviewed TMS in MSA, PSP, CBD and Lewy body disease. Their abstract says most reviewed studies reported benefit for movement and non-movement symptoms, but the evidence is preliminary and large double-blind trials are missing. It gives no separate conclusions or numbers for each condition.
What do these findings mean, and what do they not show?
Small controlled studies in MSA have reported differences from sham on certain scores, and the field is still being explored. That suggests the method may be worth studying, but it does not make TMS an established treatment.
The studies do not show that TMS:
- slows disease progression or extends life
- reduces falls in daily life
- keeps working after the sessions end
- helps in CBD or DLB
Protocols also differ from study to study, from a single session in PSP to ten in MSA, so there is no standard programme to describe. How a session goes, and what the risks are, is explained on What is TMS Parkinson Plus application?. TMS in general is described on What is TMS: brain-targeted stimulation.
What can you ask if a centre offers TMS for these conditions?
If a centre suggests TMS for one of these conditions, it is reasonable to ask openly about the evidence. Questions to consider:
- Is TMS cleared by a regulator or recommended in a guideline for this condition?
- Is the treatment part of a research study? What will be measured, and for how long will you be followed?
- Which brain area, how many sessions and which protocol are proposed, and which study supports them?
- Have implants or devices that could rule TMS out been checked, such as a pacemaker or a brain stimulator?
- Will physiotherapy, speech therapy and the rest of supportive care continue alongside?
Cleveland Clinic says metal or electronic implants in the head or neck that cannot be removed, and pacemakers or defibrillators, are reasons not to have TMS. It calls seizure the most serious side effect and very rare, with a higher risk in people with epilepsy or a seizure history. A seizure after you have left the clinic needs emergency help. Existing medicines should not be stopped or changed for TMS without the doctor who prescribes them. The wider picture of these conditions is on Overview of Parkinson Plus disease, and the steps of ordinary care are on Parkinson Plus treatment, the care process.
Sources
- Zhang and colleagues, Effects of Non-invasive Brain Stimulation on Multiple System Atrophy: A Systematic Review (2021)
- Pilotto and colleagues, Cerebellar rTMS in PSP: a Double-Blind Sham-Controlled Study (2021)
- Civardi and colleagues, Effects of slow repetitive transcranial magnetic stimulation in patients with corticobasal syndrome (2015)
- Petsani and colleagues, Therapeutic Application of rTMS in Atypical Parkinsonian Disorders (2021)
- Lefaucheur and colleagues, Evidence-based guidelines on the therapeutic use of rTMS: An update (2020)
- Cleveland Clinic: Transcranial Magnetic Stimulation (TMS)
This article is for general information and does not replace medical diagnosis or treatment. Please consult your physician for advice about your own condition.
Assoc. Prof. Dr. Mehmet Sorar
Neurosurgeon in Ankara. Graduated from Gazi University Faculty of Medicine in 1997, specialist since 2004, associate professor since 2019. Full CV
Related treatment page: TMS Tedavisi